

Market Announcement

19 October 2022

Anatara Lifesciences Limited (ASX: ANR) – Trading Halt

Description

The securities of Anatara Lifesciences Limited ('ANR') will be placed in trading halt at the request of ANR, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 21 October 2022 or when the announcement is released to the market.

Issued by

Alan Zhao

Compliance Officer, Listings Compliance (Sydney)

ASX Release

Ms Lisa Banh
Senior Advisor, Listings Compliance
ASX Compliance Pty Limited
20 Bridge Street
Sydney NSW 2000

Email tradinghaltssydney@asx.com.au

Dear Lisa,

Request for Trading Halt

MELBOURNE, 19 October 2022: Anatara Lifesciences Limited (ASX: ANR) ("**Anatara**" or "**Company**") requests an immediate trading halt be granted by ASX Limited in respect of its shares from commencement of trading on Wednesday, 19 October 2022.

The trading halt is requested pending an announcement by Anatara in relation to a capital raising (**Capital Raising**).

In accordance with ASX Listing Rule 17.1, Anatara provides the following information:

- (a) the trading halt is necessary for Anatara to make an announcement to the market in relation to the Capital Raising;
- (b) the trading halt should remain in place until the commencement of trading on Friday, 21 October 2022 unless, before that time, it makes an announcement in relation to the Capital Raising or requests that the trading halt be lifted;
- (c) Anatara is not aware of any reason why the trading halt should not be granted; and
- (d) Anatara is not aware of any other information necessary to inform the market about the trading halt.

Yours sincerely



Stephen Denaro
Company Secretary
Anatara Lifesciences Limited

--Ends--

Released with authority of the Board.

For more information please contact:

Dr. David Brookes
Chair, Anatara Lifesciences Ltd
Ph: +61 (0) 411 712 579 Email: dbrookes@anatara.com

Dirk van Dissel
Candour Advisory
Investor Relations
PH: +61 (0) 408 326 367 Email: dirk@candouradvisory.com.au

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX: ANR) is developing and commercialising innovative, evidence-based solutions for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.